Oppenheimer & Co. Inc. Acquires New Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Oppenheimer & Co. Inc. acquired a new stake in United Therapeutics Co. (NASDAQ:UTHR) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 3,854 shares of the biotechnology company’s stock, valued at approximately $301,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Nissay Asset Management Corp Japan ADV grew its position in shares of United Therapeutics by 2.9% in the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 5,029 shares of the biotechnology company’s stock valued at $590,000 after purchasing an additional 144 shares during the period. NEXT Financial Group Inc lifted its stake in United Therapeutics by 72.7% in the 2nd quarter. NEXT Financial Group Inc now owns 475 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 200 shares in the last quarter. Gabelli Funds LLC bought a new stake in United Therapeutics in the 2nd quarter valued at approximately $390,000. Swiss National Bank lifted its stake in United Therapeutics by 2.6% in the 1st quarter. Swiss National Bank now owns 145,200 shares of the biotechnology company’s stock valued at $17,042,000 after acquiring an additional 3,700 shares in the last quarter. Finally, AGF Investments LLC lifted its stake in United Therapeutics by 7.9% in the 2nd quarter. AGF Investments LLC now owns 20,383 shares of the biotechnology company’s stock valued at $1,591,000 after acquiring an additional 1,499 shares in the last quarter. Institutional investors and hedge funds own 94.16% of the company’s stock.

In other news, Director Raymond Dwek sold 3,750 shares of the company’s stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $76.11, for a total transaction of $285,412.50. Following the sale, the director now owns 3,750 shares in the company, valued at approximately $285,412.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Richard Giltner sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $79.05, for a total value of $395,250.00. Following the sale, the director now owns 5,000 shares in the company, valued at approximately $395,250. The disclosure for this sale can be found here. Corporate insiders own 8.80% of the company’s stock.

UTHR has been the topic of several research reports. Wedbush restated a “buy” rating and issued a $273.00 target price on shares of United Therapeutics in a research note on Thursday, August 1st. Credit Suisse Group upgraded United Therapeutics from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $98.00 to $101.00 in a research note on Monday, July 1st. BidaskClub cut United Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday. Jefferies Financial Group upgraded United Therapeutics from an “underperform” rating to a “hold” rating and set a $90.00 target price on the stock in a research note on Thursday, August 1st. Finally, UBS Group upgraded United Therapeutics from a “sell” rating to a “neutral” rating and cut their target price for the company from $115.00 to $94.00 in a research note on Friday, May 17th. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $120.36.

Shares of United Therapeutics stock traded down $2.79 on Thursday, reaching $80.13. 38,724 shares of the company were exchanged, compared to its average volume of 541,395. United Therapeutics Co. has a one year low of $74.31 and a one year high of $129.59. The company has a market capitalization of $3.64 billion, a price-to-earnings ratio of 5.98 and a beta of 0.92. The company has a current ratio of 4.62, a quick ratio of 4.41 and a debt-to-equity ratio of 0.31. The company has a 50-day moving average of $80.73 and a 200 day moving average of $93.03.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $4.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.40 by $2.26. United Therapeutics had a negative return on equity of 4.54% and a negative net margin of 7.69%. The company had revenue of $373.60 million for the quarter, compared to analysts’ expectations of $331.78 million. Analysts predict that United Therapeutics Co. will post -1.96 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Recommended Story: Why are percentage gainers important?

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit